Trial Profile
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs Enobosarm (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Feb 2024 Status changed to completed.
- 15 May 2023 Planned End Date changed from 3 Nov 2021 to 28 Dec 2023.
- 15 Dec 2020 Planned End Date changed from 3 Nov 2020 to 3 Nov 2021.